NOT-HL-19-674: Notice of NHLBI Participation in PA-19-112 "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)"

Notice of NHLBI Participation in PA-19-112 "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)"

Notice Number: NOT-HL-19-674

Key Dates
Release Date: January 17, 2019

Related Announcements

PA-19-112

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-19-112 "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)".

The following sections of PA-19-112 have been modified (shown in italics):

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.393, 93.837

Section VII. Agency Contacts

Scientific/Research Contact(s)

Patrice Desvigne-Nickens, M.D.

National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0504
Email: [email protected]

Financial/Grants Management Contact(s)

Tyrone Smith

National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8053
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Patrice Desvigne-Nickens, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0504
Email: [email protected]